Lubiprostone-Amitiza is not approved for use in children and men. (FDA) !!!
Who is joking ?
In clinical trials, the most common adverse event was nausea (31%). Other adverse events (≥5% of patients) included diarrhea (13%), headache (13%), abdominal distention (5%), abdominal pain (5%), flatulence (6%), sinusitis (5%) and vomiting (5%).
Who is joking ?????
I quote :
"In an 8k filing posted last night, Sucampo Pharmaceuticals (SCMP) announced that it would not renew COO James Egan`s employment agreement, which expires on September 14, 2012. Mr. Egan was leading a shoot-to-kill battle against Takeda, the company`s marketing partner for SCMP`s lead product, Amitiza, for lack of performance in marketing the Irritable Bowel Syndrome (IBS) treatment. This could be good news for SCMP shares today as investors may be relieved to see the company pursue a more balanced strategy rather than waging war against its commercial partner."